For collaboration Sample Clauses

For collaboration. You can create content, which may contain information about you, and grant permission to others to see, share, edit, copy and download that content based on settings you or your administrator (if applicable) select. Some of the collaboration features of the Services display some or all of your profile information to other Service users when you share or interact with specific content. For example, when you join a meeting, we display your profile picture and name so that other users with access to the meeting understand who they are interacting with. When you send a chat message to another user or a group of users in the meeting, the recipients will see your name next to the chat message. Similarly, when you message or send invitations to other users, your name and email is displayed as the sender of that message. Please be aware that some aspects of the Services like public pages or event registration pages can be made publicly available, meaning any content posted, including information about you, can be publicly viewed and indexed by and returned in search results of search engines. You can confirm whether certain Service properties are publicly visible from within the Services or by contacting the relevant administrator.
Sample 1
AutoNDA by SimpleDocs
For collaboration. There are many quality supplementary learning resources and teacher support programs addressing various aspects of energy and the environment, including those of the Pembina Institute, Wild BC, Pollution Probe, the SEEDS Foundation, and the Suzuki Foundation. The need is for collaboration that addresses needs (gaps), encourages better use of existing resources, avoids duplication and adds value—resulting in a concerted, collaborative effort that yields demonstrable results. Why Xxxxxxxxxxxxx.xx? In 2001, after a decade of national experience with climate change and energy-environment education (including the widely acclaimed Climate Change Education and Action Kit for high schools), teacher training workshops, and electronic publishing of on-line supplementary learning resources (xx-xxxxxx.xx and xxxxxxxxxxxxxxxxxxxxxx.xx) the Pembina Institute stepped back to re-assess what was needed to increase the effectiveness of education on the environment- energy front. With support from the Alberta Government, and augmenting it’s own expertise by acquiring the education team that developed the award-winning Destination Conservation energy efficiency education program for the Tomorrow Foundation, the Institute conducted 18 months of needs assessment, consultations with teachers, curriculum review, and exploration of options for effective e-learning design. The results of this review and planning led to major shift in the organization’s energy-environment education program, and to a collaborative three year $860,000 electronic publishing and teacher engagement and training initiative that has been successfully launched for Alberta schools. It will begin widespread uptake in classrooms for September 2005. Xxxxxxxxxxxxx.xx – Alberta serves as phase one of the Pembina Institute’s long term efforts to respond to the need for a national suite of quality Canadian e-learning programs, each customized to the requirements of the specific issues and curriculum needs of each province or territory. Building on what has been learned from the three years of development work and the ongoing delivery and implementation of Xxxxxxxxxxxxx.xx in Alberta, the Pembina Institute is now coordinating its efforts with other major energy-environment education players interested in addressing the need for this type of effort in British Columbia and is seeking partners and sponsors for Xxxxxxxxxxxxx.xx British Columbia. Phase two of the program will also include a similar approach for British C...
Sample 1

Related to For collaboration

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • AREAS OF COLLABORATION The School will collaborate under Xxxx Innovation Mission to establish, operate and support ATL in India within the school premises with financial support from NITI Aayog.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Third Party Technology The Company makes use of third party technology to collect information required for traffic measurement, research, and analytics. Use of third party technology entails data collection. We therefore would like to inform clients the Company enables third parties to place or read cookies located on the browsers of users entering the Company’s domain. Said third parties may also use web beacons to collect information through advertising located on the Company’s web site. Please note that you may change your browser settings to refuse or disable Local Shared Objects and similar technologies; however, by doing so you may be disabling some of the functionality of Company’s services.

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.

  • Research Project 3.1 These Materials and Data will be used by Recipient's PI solely in connection with the Research Project, as named and described in the attached research application (insert Research Project name below):

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.